Corvus Pharmaceuticals To Present Interim Phase 1 Data Of Soquelitinib For Atopic Dermatitis On December 18

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. This will announce interim results from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis on December 18, 2024. The trial is randomized, double-blind, and placebo-controlled. The data will be shared through a press release and discussed during a conference call and webcast.

The company will host the conference call and webcast on December 18, 2024, at 8:00 a.m. ET / 5:00 a.m. PT, which will provide an overview of the clinical data from the soquelitinib study for atopic dermatitis.